Harmony Biosciences Holdings, Inc.Harmony Biosciences Holdings, Inc.Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

No trades
See on Supercharts
Market capitalization
‪1.67 B‬USD
‪128.85 M‬USD
‪582.02 M‬USD
‪30.75 M‬
Beta (1Y)
2.47

About Harmony Biosciences Holdings, Inc.

CEO
Jeffrey M. Dayno
Headquarters
Plymouth Meeting
Employees (FY)
246
Founded
2017
ISIN
US4131971040
FIGI
BBG00WBPG4C2
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of HRMY is 29.83 USD — it has decreased by 4.57% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Harmony Biosciences Holdings, Inc. stocks are traded under the ticker HRMY.
Harmony Biosciences Holdings, Inc. is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Harmony Biosciences Holdings, Inc. has a max estimate of 56.00 USD and a min estimate of 30.00 USD.
HRMY earnings for the last quarter are 0.63 USD whereas the estimation was 0.67 USD which accounts for −5.34% surprise. Estimated earnings for the next quarter are 0.72 USD. See more details about Harmony Biosciences Holdings, Inc. earnings.
Harmony Biosciences Holdings, Inc. revenue for the last quarter amounts to ‪160.27 M‬ USD despite the estimated figure of ‪147.83 M‬ USD. In the next quarter revenue is expected to reach ‪169.02 M‬ USD.
Yes, you can track Harmony Biosciences Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, HRMY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Harmony Biosciences Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
HRMY reached its all-time high on Dec 5, 2022 with the price of 62.09 USD, and its all-time low was 18.61 USD and was reached on Oct 13, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 12, 2024, the company has 246.00 employees. See our rating of the largest employees — is Harmony Biosciences Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Harmony Biosciences Holdings, Inc. EBITDA is ‪216.39 M‬ USD, and current EBITDA margin is 37.18%. See more stats in Harmony Biosciences Holdings, Inc. financial statements.